Deciphera Pharmaceuticals (NASDAQ:DCPH) Downgraded by Leerink Partnrs to Market Perform

Leerink Partnrs cut shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) from an outperform rating to a market perform rating in a report issued on Monday morning, Zacks.com reports. A number of other brokerages also recently issued reports on DCPH. Stifel Nicolaus raised their price objective on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave […]

Leave a Reply

Your email address will not be published.

Previous post Northland Capmk Brokers Reduce Earnings Estimates for OneMain Holdings, Inc. (NYSE:OMF)
Next post The London Concours 2023: Wild Cards Concours Class